tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Silence Therapeutics Passes Key Resolutions at AGM
PremiumCompany AnnouncementsSilence Therapeutics Passes Key Resolutions at AGM
2M ago
Buy Rating on Silence Therapeutics: Promising Developments in Divesiran and Zerlasiran Programs
Premium
Ratings
Buy Rating on Silence Therapeutics: Promising Developments in Divesiran and Zerlasiran Programs
2M ago
Promising Phase 1 Data and Strong Mechanistic Rationale Justify Buy Rating for Silence Therapeutics’ Divesiran in Polycythemia Vera
Premium
Ratings
Promising Phase 1 Data and Strong Mechanistic Rationale Justify Buy Rating for Silence Therapeutics’ Divesiran in Polycythemia Vera
2M ago
Silence Therapeutics reports Q1 EPS (20c), consensus (41c)
PremiumThe FlySilence Therapeutics reports Q1 EPS (20c), consensus (41c)
3M ago
Silence Therapeutics Announces Board Changes and New Director
Premium
Company Announcements
Silence Therapeutics Announces Board Changes and New Director
3M ago
Silence Therapeutics: Strategic Focus and Strong Financials Poised for Growth with Promising RNAi Pipeline
Premium
Ratings
Silence Therapeutics: Strategic Focus and Strong Financials Poised for Growth with Promising RNAi Pipeline
5M ago
Silence Therapeutics price target lowered to $30 from $31 at Jefferies
PremiumThe FlySilence Therapeutics price target lowered to $30 from $31 at Jefferies
6M ago
Silence Therapeutics reports FY25 net loss  33c vs. 49c loss last year
Premium
The Fly
Silence Therapeutics reports FY25 net loss 33c vs. 49c loss last year
6M ago
Silence Therapeutics extends projected cash runway into 2027
Premium
The Fly
Silence Therapeutics extends projected cash runway into 2027
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100